<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058422</url>
  </required_header>
  <id_info>
    <org_study_id>02-090</org_study_id>
    <secondary_id>MSKCC-02090</secondary_id>
    <nct_id>NCT00058422</nct_id>
  </id_info>
  <brief_title>Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma</brief_title>
  <official_title>A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can&#xD;
      locate cancer cells and either kill them or deliver radioactive cancer-killing substances to&#xD;
      them without harming normal cells. Drugs used in chemotherapy use different ways to stop&#xD;
      cancer cells from dividing so they stop growing or die. Combining rituximab and combination&#xD;
      chemotherapy with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining rituximab and combination&#xD;
      chemotherapy with yttrium Y 90 ibritumomab tiuxetan in treating older patients who have&#xD;
      B-cell lymphoma that has not been previously treated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients age 60 and over with&#xD;
           previously untreated diffuse large B-cell lymphoma treated with rituximab,&#xD;
           cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combined with&#xD;
           yttrium Y 90 ibritumomab tiuxetan.&#xD;
&#xD;
        -  Determine the incidence of adverse experiences, hematologic toxicity (WBC, hemoglobin,&#xD;
           and platelet nadirs; and transfusion requirements), cardiac toxicity (incidence of left&#xD;
           ventricular dysfunction and cardiomyopathy by echocardiography), and the development of&#xD;
           human antimouse antibody/human anti-chimeric antibody in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the predictive value of detecting minimal residual disease by molecular&#xD;
           techniques for future relapse/recurrence in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the response rate of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the red blood cell transfusion requirements, change in hemoglobin from&#xD;
           baseline, and incidence of anemia with prophylactic darbepoetin alfa support in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the conversion rate to complete remission in patients treated with ibritumomab&#xD;
           tiuxetan who achieve a partial remission post-R-CHOP.&#xD;
&#xD;
        -  Determine the effect of darbepoetin alfa on the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized study.&#xD;
&#xD;
        -  Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV,&#xD;
           doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and&#xD;
           filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin&#xD;
           alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111&#xD;
           ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
&#xD;
      Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of&#xD;
      IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then&#xD;
      patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7.&#xD;
&#xD;
      Quality of life is assessed at baseline, before course 5 of chemotherapy, before&#xD;
      radioimmunotherapy, and at 3 months.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 4 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2003</start_date>
  <completion_date type="Actual">November 14, 2019</completion_date>
  <primary_completion_date type="Actual">November 14, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Experiences</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the incidence of adverse experiences, hematologic toxicity (WBC, hemoglobin, and platelet nadirs; and transfusion requirements), cardiac toxicity (incidence of left ventricular dysfunction and cardiomyopathy by echocardiography), and the development of human antimouse antibody/human anti-chimeric antibody in patients treated with this regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conversion Rate to Complete Remission</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 ibritumomab tiuxetan</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
    <arm_group_label>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diffuse large B-cell lymphoma, including any of the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Centroblastic&#xD;
&#xD;
               -  Immunoblastic&#xD;
&#xD;
               -  T-cell/histiocyte-rich&#xD;
&#xD;
               -  Lymphomatoid granulomatosis type&#xD;
&#xD;
               -  Anaplastic large B-cell&#xD;
&#xD;
               -  Plasmablastic&#xD;
&#xD;
               -  Mediastinal&#xD;
&#xD;
               -  Intravascular large B-cell lymphoma&#xD;
&#xD;
          -  Previously untreated&#xD;
&#xD;
          -  High-intermediate or high-risk disease, defined by an age-adjusted international&#xD;
             prognostic index score of 2 or 3 (with 1 point each assigned for a ECOG greater than&#xD;
             1/Karnofsky less than 80%, lactate dehydrogenase greater than normal, and stage III or&#xD;
             IV)&#xD;
&#xD;
          -  Lymphomas with discordant histology and a diffuse large B-cell component are eligible&#xD;
&#xD;
          -  Must have an initial diagnostic specimen that is CD20+&#xD;
&#xD;
          -  At least Ann Arbor stage II disease&#xD;
&#xD;
               -  No confinement of disease to an involved-field radiotherapy port (stage I or&#xD;
                  limited stage II disease)&#xD;
&#xD;
          -  Bidimensionally measurable disease with at least 1 lymph node at least 2.0 cm by 2.0&#xD;
             cm by physical examination, CT scan, or positron-emission tomography&#xD;
&#xD;
          -  Bone marrow cellularity greater than 15%&#xD;
&#xD;
          -  No known brain or leptomeningeal metastases&#xD;
&#xD;
          -  No primary effusion lymphomas&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  60 and over* NOTE: *Patients 60 to 65 years of age must be deemed ineligible for&#xD;
             autologous stem cell transplantation&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (except for Gilbert's disease)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL* OR&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min* NOTE: *Patients not meeting either&#xD;
             criterion but who have renal insufficiency directly related to lymphomatous&#xD;
             involvement of the kidneys or renal collecting system are allowed&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac ejection fraction at least 50% by echocardiogram&#xD;
&#xD;
          -  No acute myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  B12 and folate greater than the lower limit of normal&#xD;
&#xD;
          -  Transferrin saturation at least 15%&#xD;
&#xD;
          -  Ferritin greater than 10 µg/L&#xD;
&#xD;
          -  At least 6 weeks since prior RBC donation&#xD;
&#xD;
          -  No active seizure disorder&#xD;
&#xD;
               -  Prior seizure disorder allowed if free of antiseizure medication and evidence of&#xD;
                  seizure activity for the past 5 years&#xD;
&#xD;
          -  No concurrent uncontrolled medical problems that would preclude administration of&#xD;
             chemotherapy or radioimmunotherapy&#xD;
&#xD;
          -  No other concurrent malignancy treated with chemotherapy or radiotherapy except&#xD;
             adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior RBC transfusion&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
          -  No other concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy (one course of R-CHOP allowed)&#xD;
&#xD;
          -  No other concurrent standard or investigational chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No more than 7 consecutive days of prior steroids (premedication allowed for prior&#xD;
             intravenous contrast allergy)&#xD;
&#xD;
          -  No other concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A. Hamlin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <results_first_submitted>September 23, 2020</results_first_submitted>
  <results_first_submitted_qc>October 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2007</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT00058422/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</title>
          <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</title>
          <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" lower_limit="62" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</title>
            <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Dead</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <time_frame>2 years</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</title>
            <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival</title>
        <time_frame>2 years</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</title>
            <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Experiences</title>
        <description>Determine the incidence of adverse experiences, hematologic toxicity (WBC, hemoglobin, and platelet nadirs; and transfusion requirements), cardiac toxicity (incidence of left ventricular dysfunction and cardiomyopathy by echocardiography), and the development of human antimouse antibody/human anti-chimeric antibody in patients treated with this regimen.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</title>
            <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Experiences</title>
          <description>Determine the incidence of adverse experiences, hematologic toxicity (WBC, hemoglobin, and platelet nadirs; and transfusion requirements), cardiac toxicity (incidence of left ventricular dysfunction and cardiomyopathy by echocardiography), and the development of human antimouse antibody/human anti-chimeric antibody in patients treated with this regimen.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conversion Rate to Complete Remission</title>
        <time_frame>2 years</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</title>
            <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Conversion Rate to Complete Remission</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>R-CHOP and Ibritumomab Tiuxetan (Zevalin)</title>
          <description>Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.&#xD;
Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac left vent</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cardiovascular, Arrhythmia other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cardiovascular, other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Supravent arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain/cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Colititis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diarrhea (Pts w/out col)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>GI, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w.out neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Infection with grade 3/4 neut</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Infection/Feb Neut-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin (Hgb)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neurology, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delusions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pulmonary, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Derm, skin other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hemoglobin (Hgb)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supravent arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cardiovascular, Arrhythmia other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Colititis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diarrhea (Pts w/out col)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w.out neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Infection with grade 3/4 neut</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Infection/Feb Neut-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul A. Hamlin, M.D.</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-608-1667</phone>
      <email>hamlinp@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

